Reduction of ATRs

Platelet concentrates (PC) treated with the INTERCEPTTM Blood System can either be stored in plasma or in a mixture of plasma and platelet additive solution (PAS).

A French retrospective analysis showed that the incidence of acute transfusion reactions (ATR) per platelet concentrate and per patient was significantly reduced after the implementation of PAS and further reduced after the implementation of INTERCEPT.¹

 

	Number of ATRs by 1000 transfused PCs	% of patients with PC-related ATRs
PCs in plasma	5.3	2.9
PCs in PAS	2.7	2.0
PCs in PAS + INTERCEPT	1.4	1.7

 

 

 

 

 

 

Swiss national haemovigilance data has also shown a decrease in the number and severity of non-infection-related transfusion reactions after PC transfusion. Swissmedic concluded that, ‘The most likely explanation for this is the generally lower plasma content of pathogen-inactivated platelet concentrates, which reduces allergic and febrile transfusion reactions to plasma constituent’.²

The introduction of the pathogen inactivation (PI) process has led to a reduction in the number and severity of non-infection-related transfusion reactions after platelet concentrates transfusion’.

Swissmedic Annual Haemovigilance Report, 2014

 

 

Sources:

1. Cazenave JP, et al., Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period, Transfusion (2011) 51, 622-629

2. Swissmedic Annual Haemovigilance Report, 2014